Výsledky vyhledávání - "Roula B. Qaqish"

Change in the hepatic profile of hepatitis C virus genotype 4–infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE‐II study

Autor: Gamal Esmat, Reham Soliman, Naglaa Allam, N. Mobashery, Mohamed Hassany, Gamal Shiha, Sarah Kopecky-Bromberg, Negar N. Alami, Mohammad A. Mohey, Coleen Hall, Rabab Fouad, Roula B. Qaqish, Imam Waked

Publikováno v: Journal of Medical Virology

In AGATE‐II, treatment with ombitasvir coformulated with paritaprevir/ritonavir plus ribavirin (RBV) in Egyptians infected with hepatitis C virus genotype 4 resulted in high rates of sustained virologic response at post‐treatment week 12. This su

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5947b56beb9f4c3738d73cebfdd0ebd
https://doi.org/10.1002/jmv.25243

Zobrazit plný text záznamu

Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial

Autor: Coleen Hall, Mohamed Hassany, Reham Soliman, N. Mobashery, Tarik Asselah, Rebecca Redman, Gamal Shiha, Roula B. Qaqish, Mohammad A. Mohey, Gamal Esmat, Ayman Yosry, Imam Waked, Wahid Doss, Naglaa Allam, Naglaa Zayed

Publikováno v: The Lancet Gastroenterology & Hepatology. 1:36-44

In Egypt, chronic hepatitis C virus (HCV) infection occurs in around 10% of the population (about 8 million individuals), and is a leading cause of liver cirrhosis, hepatocellular carcinoma, and mortality. Although HCV genotype 4 constitutes about 20

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3015ede8611b28d5be89e1e866c076b4
https://doi.org/10.1016/s2468-1253(16)30002-4

Zobrazit plný text záznamu

Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial

Autor: Peter Ferenci, Tami Pilot-Matias, N. Mobashery, Jordan J. Feld, George V. Papatheodoridis, Christophe Hézode, Christophe Moreno, Tarek Hassanein, Stefan Zeuzem, Yao Yu, Roula B. Qaqish, Rebecca Redman, Tarik Asselah, Magdy Elkhashab

Publikováno v: The Lancet Gastroenterology & Hepatology. 1:25-35

Hepatitis C virus (HCV) genotype 4 infection is most commonly reported in sub-Saharan Africa and the Middle East; however, prevalence is increasing worldwide through immigration. HCV genotype 4 accounts for 20% of all infections, but clinical trial d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e0776d3fb6c36fa7d75d5d9ac7096ff
https://doi.org/10.1016/s2468-1253(16)30001-2

Zobrazit plný text záznamu

Lopinavir/Ritonavir Combined with Raltegravir or Tenofovir/Emtricitabine in Antiretroviral-Naive Subjects: 96-Week Results of the PROGRESS Study

Autor: Roger Trinh, Thomas Podsadecki, Joseph Gathe, Ruth Soto-Malave, Michael Norton, Jacques Reynes, Min Tian, Linda M Fredrick, Roula B Qaqish, Angela Nilius, Federico Pulido

Publikováno v: AIDS Research and Human Retroviruses. 29:256-265

Alternative combinations of antiretrovirals (ARVs) are desired to increase treatment options for HIV-infected patients. PROGRESS was a randomized, open-label, 96-week pilot study comparing a regimen of lopinavir/ritonavir (LPV/r) 400/100 mg twice dai

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bf9a60498b7c850279bc106cab758e6
https://doi.org/10.1089/aid.2011.0275

Zobrazit plný text záznamu

Meta-analysis of once-daily and twice-daily lopinavir/ritonavir combined with NRTIs in HIV-1-infected, antiretroviral-naive patients

Autor: Martin S. King, Ronald D’Amico, Jean van Wyk, Kimberly Hollar, Kelly White, Michael Norton, Yi-Lin Chiu, Roula B Qaqish

Publikováno v: Future Virology. 7:103-113

Aims: Several studies reported similar virologic responses for lopinavir/ritonavir (LPV/r) 800/200 mg once-daily (q.d.)-containing regimens or LPV/r 400/100 mg twice-daily (b.i.d.)-containing regimens in antiretroviral-naive patients. However, the vi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a9f946becf20554b158f06f62858f11e
https://doi.org/10.2217/fvl.11.127

Zobrazit plný text záznamu

Amprenavir and Lopinavir Pharmacokinetics following Coadministration of Amprenavir or Fosamprenavir with Lopinavir/Ritonavir, with or without Efavirenz

Autor: Patricia Barditch-Crovo, Christine Radebaugh, Wasif A. Khan, Paul A. Pham, Charles Flexner, Teresa L. Parsons, Kathryn A. Carson, Michelle Parish, Roula B Qaqish, Craig W. Hendrix, Gary E Pakes

Publikováno v: Antiviral Therapy. 12:963-970

Background Amprenavir (APV), fosamprenavir (FPV), lopinavir (LPV), ritonavir (RTV) and efavirenz (EFV) are to varying degrees substrates, inducers and inhibitors of CYP3A4. Coadministration of these drugs might result in complex pharmacokinetic drug-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::995941525d1c4f5ec94bd3cf3d876f40
https://doi.org/10.1177/135965350701200614

Zobrazit plný text záznamu

Successful Treatment with Atazanavir and Lopinavir/Ritonavir Combination Therapy in Protease Inhibitor-Susceptible and Protease Inhibitor-Resistant HIV-Infected Patients

Autor: Robert R. Redfield, Bruce L. Gilliam, Kirk M. Chan-Tack, Lori E. Fantry, Roula B. Qaqish, Richard A. Rode

Publikováno v: AIDS Patient Care and STDs. 20:745-759

The combination of atazanavir (ATV) plus lopinavir/ritonavir (LPV/r) has been used in practice. However, clinical data supporting its use are limited. The objective of this study was to evaluate the efficacy and tolerability of regimens with ATV + LP

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8353016b49648350764fa5594009284
https://doi.org/10.1089/apc.2006.20.745

Zobrazit plný text záznamu

Adefovir dipivoxil: A new antiviral agent for the treatment of hepatitis B virus infection

Autor: Keri A. Mattes, David J. Ritchie, Roula B. Qaqish

Publikováno v: Clinical Therapeutics. 25:3084-3099

Background: Hepatitis B virus (HBV) infection is a major problem worldwide and an important cause of chronic liver disease and cirrhosis. Currently available treatments include interferon alfa-2b, lamivudine, and adefovir dipivoxil. Adefovir dipivoxi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce69eb20e03a8d38c64c3a554a6e3b1a
https://doi.org/10.1016/s0149-2918(03)90093-2

Zobrazit plný text záznamu

Management of Anemia of Chronic Disease in Patients with the Human Immunodeficiency Virus

Autor: Kristi L. Brokering, Roula B. Qaqish

Publikováno v: Pharmacotherapy. 23:1475-1485

Anemia is the most frequently encountered hematologic complication in human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome. The prevalence estimates vary widely with the severity of HIV disease. Data suggest that treatm

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f51b0c6a29b3f47333490b156da235fe
https://doi.org/10.1592/phco.23.14.1475.31949

Zobrazit plný text záznamu

Practical psychopharmacology in HIV-1 and acquired immunodeficiency syndrome

Autor: Michael J Robinson, Roula B. Qaqish

Publikováno v: Psychiatric Clinics of North America. 25:149-175

HIV-1 infection poses a challenge for psychiatrists of the medically ill. Many factors concerning the care of HIV-1-infected patients need to be considered when prescribing psychotropics. These include careful diagnosis, taking into account medical d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b165a4234fbd86e228496456547e82b8
https://doi.org/10.1016/s0193-953x(03)00056-x

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání